Find information on thousands of medical conditions and prescription drugs.

Bromhexine

A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus.

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Oral Mucolytics Provide Benefits in Chronic Bronchitis
From American Family Physician, 12/15/01 by Anne D. Walling

At least 50 percent of all smokers develop chronic bronchitis, and up to 15 percent become incapacitated because of chronic obstructive pulmonary disease (COPD). The mainstay of treatment during exacerbations is antibiotic or steroid therapy, but other agents are needed to reduce the frequency and severity of exacerbations. In some European countries, mucolytic agents (such as bromhexine or iodinated glycerol) are widely used to treat chronic bronchitis. Poole and Black conducted a meta-analysis to determine the potential benefits of mucolytic therapy.

The authors used the Cochrane Airways Group Register to search for studies of mucolytic therapy for chronic bronchitis or COPD. Four of the 27 double-blind, placebo-controlled studies they identified were excluded because they lacked information on the primary outcome. Two of the remaining studies focused on COPD, and 21 studied chronic bronchitis. The studies involved more than 2,000 patients treated with mucolytics and 2,000 patients given placebo.

Regular use of mucolytics was associated with small, nonsignificant changes in measures of pulmonary function but with significant reductions of about one-half day per month in days of illness. The chance of being free of exacerbations was approximately doubled. The calculated number to treat for one patient to remain free of exacerbations was six. Adverse effects were noted and occurred with the same frequency in treated and placebo groups.

The authors conclude that regular use of mucolytic agents modestly reduces exacerbations and the number of days of illness in patients with chronic bronchitis and COPD. The benefits may be greatest in patients with more advanced disease, but the cost-effectiveness of mucolytic therapy has not been established.

COPYRIGHT 2001 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Bromhexine
Home Contact Resources Exchange Links ebay